根据名称进行药物检索

Dihydroergotamine injection 与 Ketoconazole (Systemic)

Dihydroergotamine injection 与 Ketoconazole (Systemic)互相作用以及同时服用的可能性。

检测结果:

Dihydroergotamine injection <> Ketoconazole (Systemic)

现实性: 21.12.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用双氢麦角胺一起的药物是不建议。结合这些药物可以大大增加，血液水平和效果的双氢麦角胺，这在某些情况下可能导致过度缩小血管的身体。这可以降低血液流向重要机构，并增加的风险罕见的，但是严重的副作用，例如高血压、心脏病、中风、坏疽和(死亡的组织，通常在胳膊或一条腿，可能需要外科手术截肢). 谈谈你的医生如果你有任何疑问或关切的问题。你的医生可以规定替代品，不进行互动。你应该立即寻求医疗照顾，如果你经历剧烈的腹痛、恶心、呕吐，麻木或刺痛、肌肉疼痛或疲软、蓝色和紫色的手或脚的，苍白的，或冷的皮肤、胸部疼痛或密性，心跳不规则，严重头痛、呼吸急促、视力模糊、混乱、和/或含糊不清的语音治疗期间，双氢麦角胺. 不采取更大剂量使用或使用药物的频率比的规定。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

禁忌:共同给予有效抑制剂的CYP450 3A4包括唑抗真菌剂可以大大增加等离子浓度的麦角衍生物，其主要代谢的同工酶. 相互作用已经发生在患者接受麦角胺或双氢麦角胺与其他有效的CYP450 3A4抑制剂，如大环内酯类抗生素和蛋白酶抑制剂。临床ergotism已有报道，这可能会导致坏疽和心肌梗死在严重的情况下。即使是小的、单剂量的麦角胺导致临床显着的相互作用，偶尔造成外科手术截肢或死亡。内唑类、药物和康唑被认为是最有效的抑制剂，同时氟康唑是相对软弱及通常会导致临床显着的相互作用与CYP450 3A4基仅在剂量为200毫克/日或更多。

管理：鉴于潜在的用麦角毒性特征的周边血管痉挛、局部缺血、血栓、心动过速和高血压，同时使用麦角衍生物与康唑，酮康唑泊沙康唑或种药物被认为是禁忌。使用与其他唑抗真菌剂，其中包括氟康唑在高多的剂量，可能应该是可以避免的，如果可能的。

来源

Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42
Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7
Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18
Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771
Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3
"Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.
Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6
Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7
Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4
"Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.
Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249
Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329
Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6
Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594
Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6
Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771
Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207
Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57
"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.
Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987
Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9
Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4
Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5
"Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8